Recently, imbalance in angiogenesis, dysregulation of the extra cellular matrix and fibroproliferation rather than inflammation has been postulated to perpetuate lung fibrosis in IPF. Detection of alveolitis may therefore have little prognostic or pathogenic relevance in the assessment of these cases. The heterogeneous pathology of UIP results in BAL and trans-bronchial biopsy (TBBx) to be subject to sampling errors compounding attempts to elucidate pathogenic pathways. A noninvasive mechanism to provide a """"""""morphometric"""""""" assessment of the whole lung on a global and regional basis would be ideal. Quantitative Image Analysis (QIA) of HRCT data has shown a correlation with inflammation, angiogenesis and fibrosis and can identify these independent manifestations of IPF on a global and regional basis not possible with bronchoscopy or visual inspection of HRCT. The hypothesis is: CT-QIA can better detect the presence, extent and progression of inflammation, angiogenesis and fibrosis in patients with ILD and so can be used to distinguish patients with UIP, DIP, NSIP or NSIP with fibrosis not possible with conventional clinical, radiographic and physiologic assessment or with sampling limited BAL and TBBx.
The specific aims are to 1) develop a CT-QIA model of pulmonary fibrosis in a murine model capable of assessing the development and progression of pulmonary fibrosis 2) develop a CT-QIA model of IPF capable of distinguishing inflammation, angiogenesis and fibrosis to better characterize patients with clinically diagnosed ILD with respect to pathologically defined UIP, DIP, NSIP and NSIP with fibrosis and 3) to determine the relative progression of inflammation, angiogenesis and fibrosis in patients with clinically assessed IPF treated with Prednisone alone, or IFN-gamma and low-dose prednisone or azathioprine plus prednisone. The main objective of this project is to distinguish between angiogenesis, inflammation and fibrosis in the pathogenesis of IPF in order to better characterize their relationship to the pathogenesis of IPF and to distinguish patients with UIP, DIP, NSIP or NSIP with fibrosis not possible with conventional techniques.
| Weigt, S S; Elashoff, R M; Keane, M P et al. (2008) Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant 8:1512-22 |
| Zisman, David A; Ross, David J; Belperio, John A et al. (2007) Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 101:2153-9 |
| Zisman, David A; Karlamangla, Arun S; Ross, David J et al. (2007) High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 132:773-9 |
| Collard, Harold R; Anstrom, Kevin J; Schwarz, Marvin I et al. (2007) Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 131:897-9 |
| Keane, Michael P; Gomperts, Brigitte N; Weigt, Samuel et al. (2007) IL-13 is pivotal in the fibro-obliterative process of bronchiolitis obliterans syndrome. J Immunol 178:511-9 |
| Struyf, Sofie; Burdick, Marie D; Peeters, Elke et al. (2007) Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res 67:5940-8 |
| Strieter, Robert M; Gomperts, Brigitte N; Keane, Michael P (2007) The role of CXC chemokines in pulmonary fibrosis. J Clin Invest 117:549-56 |
| Mohsenin, Amir; Burdick, Marie D; Molina, Jose G et al. (2007) Enhanced CXCL1 production and angiogenesis in adenosine-mediated lung disease. FASEB J 21:1026-36 |
| Strieter, Robert M; Burdick, Marie D; Mestas, Javier et al. (2006) Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42:768-78 |
| Gomperts, Brigitte N; Strieter, Robert M (2006) Chemokine-directed metastasis. Contrib Microbiol 13:170-90 |
Showing the most recent 10 out of 38 publications
